Literature DB >> 3680995

Comparison of Chlamydia trachomatis serovars causing rectal and cervical infections.

R C Barnes1, A M Rompalo, W E Stamm.   

Abstract

We used monoclonal antibodies capable of distinguishing serovars of Chlamydia trachomatis to compare 314 cervical isolates with 150 rectal isolates from homosexual men. The isolates were obtained from patients attending a sexually transmitted diseases clinic over a two-year study period. The serovar distribution of cervical and rectal isolates differed significantly. Serovar D/D' was found in 53% of the rectal isolates but in only 18% of cervical isolates (P less than .0001). Serovar E was the predominant serovar in cervical isolates (32%) but was found in only 6% of rectal isolates (P less than .0001). Serovars B, I/I', H, and K were isolated from 2%-7% of cervical specimens but were not found in rectal isolates. There was a significant decline in the proportion of rectal infections caused by serovar D/D' over the study period, and clustering of infections caused by other serovars was observed. Serotyping using monoclonal antibodies provides a powerful tool for investigating the epidemiology of sexually transmitted C. trachomatis infections.

Entities:  

Mesh:

Year:  1987        PMID: 3680995     DOI: 10.1093/infdis/156.6.953

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

1.  Urogenital Chlamydia trachomatis serovars in men and women with a symptomatic or asymptomatic infection: an association with clinical manifestations?

Authors:  S A Morré; L Rozendaal; I G van Valkengoed; A J Boeke; P C van Voorst Vader; J Schirm; S de Blok; J A van Den Hoek; G J van Doornum; C J Meijer; A J van Den Brule
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Population-based genetic and evolutionary analysis of Chlamydia trachomatis urogenital strain variation in the United States.

Authors:  Kim Millman; Carolyn M Black; Robert E Johnson; Walter E Stamm; Robert B Jones; Edward W Hook; David H Martin; Gail Bolan; Simon Tavaré; Deborah Dean
Journal:  J Bacteriol       Date:  2004-04       Impact factor: 3.490

3.  Serovar distribution of urogenital C trachomatis isolates in Germany.

Authors:  H Näher; D Petzoldt
Journal:  Genitourin Med       Date:  1991-04

4.  Lymphogranuloma venereum prevalence in Sweden among men who have sex with men and characterization of Chlamydia trachomatis ompA genotypes.

Authors:  Markus Klint; Margareta Löfdahl; Carolina Ek; Asa Airell; Torsten Berglund; Björn Herrmann
Journal:  J Clin Microbiol       Date:  2006-09-13       Impact factor: 5.948

5.  Chlamydia trachomatis serovars causing urogenital infections in women in Melbourne, Australia.

Authors:  Nichole A Lister; Christopher K Fairley; Sepehr N Tabrizi; Suzanne Garland; Anthony Smith
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

6.  Comparison of immunotyping of Chlamydia trachomatis by indirect fluorescent-antibody staining and radioimmunoassay.

Authors:  B J van der Pol; R B Jones
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

7.  Serotyping of Chlamydia trachomatis by indirect fluorescent-antibody staining of inclusions in cell culture with monoclonal antibodies.

Authors:  S P Wang; J T Grayston
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

8.  Serovars of Chlamydia trachomatis causing postabortion salpingitis.

Authors:  K Persson; S Osser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-09       Impact factor: 3.267

9.  External quality assessment for detection of Chlamydia trachomatis.

Authors:  V J Chalker; H Vaughan; P Patel; A Rossouw; H Seyedzadeh; K Gerrard; V L A James
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

10.  Chlamydia trachomatis serovar differentiation by direct sequence analysis of the variable segment 4 region of the major outer membrane protein gene.

Authors:  E Poole; I Lamont
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.